Postoperative Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Postoperative Pain Market Outlook

Thelansis’s “Postoperative Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Postoperative Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Postoperative Pain Overview

Postoperative pain throughout the body encompasses discomfort experienced across various areas, including joints, muscles, head, and limbs, often accompanied by restlessness, insomnia, sweating irregularities, fatigue, reduced appetite, and sometimes limb dysfunction. This type of pain typically emerges following significant surgical procedures, sometimes exacerbating pre-existing generalized body pain. Its intensity peaks within 24-48 hours post-surgery and gradually diminishes as the surgical site heals. In about 10% of surgical cases, acute postoperative pain can transition to chronic postsurgical pain, characterized by neuropathic features that are resistant to opioid treatment. Chronic body-wide pain, especially in the entire back, may also manifest, sometimes worsening acutely post-operation. Symptoms may include headaches, a stiff neck, joint pain, cold intolerance, mild fever, and specific pulse irregularities, notably at the Lung position. Inadequate management of postoperative pain can impede recovery, functional capabilities, and overall quality of life, elevating the risk of persistent pain and surgical complications. Pharmacological approaches to pain management may entail temporary escalation of opioid analgesics and the utilization of continuous regional block techniques immediately post-surgery.

• Globally, a substantial number of major surgeries are performed annually, with the USA alone witnessing approximately 40 to 50 million procedures. A staggering 80% of surgical patients report experiencing postoperative pain, with 88% of them describing their pain levels as moderate, severe, or extreme.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: